Sparsentan
FDA-approved product (tablet, oral), marketed as Filspari.
- Registered studies
- 11
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- IGA glomerulonephritis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other agents acting on the renin-angiotensin system
- FDA pharmacologic class
- Angiotensin 2 Receptor Blocker; Endothelin Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
11registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sparsentan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
NCT07224776 · start 2026-07-10
Registered record
- Registry ID
- NCT07224776
- Conditions
- Proteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic Range
- Interventions
- sparsentan; No sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2026-07-10
- Completion
- 2028-12-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic RangeInterventionsparsentan; No sparsentanPhasePhase 1Registry statusRecruitingClinical Experience With Sparsentan in Switzerland in IgA Nephropathy
NCT07555301 · start 2026-06-01
Registered record
- Registry ID
- NCT07555301
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- sparsentan; sparsentan
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2026-06-01
- Completion
- 2029-12-31
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIgA Nephropathy (IgAN)Interventionsparsentan; sparsentanPhaseNot recordedRegistry statusNot yet recruitingSparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121 · start 2025-10-07
Registered record
- Registry ID
- NCT07219121
- Conditions
- Proteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney Transplant
- Interventions
- Sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2025-10-07
- Completion
- 2027-05
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney TransplantInterventionSparsentanPhasePhase 4Registry statusActive not recruitingA Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760 · start 2023-05-19
Registered record
- Registry ID
- NCT05856760
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2023-05-19
- Completion
- 2024-10-25
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmunoglobulin A NephropathyInterventionSparsentanPhasePhase 2Registry statusCompletedETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
NCT05630612 · start 2022-12-08
Registered record
- Registry ID
- NCT05630612
- Conditions
- ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases
- Interventions
- Sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2022-12-08
- Completion
- 2027-09-01
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionANCA Associated Vasculitis; Cardiovascular Diseases; Kidney DiseasesInterventionSparsentanPhasePhase 2Registry statusActive not recruitingStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986 · start 2021-08-12
Registered record
- Registry ID
- NCT05003986
- Conditions
- Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis; Alport Syndrome
- Interventions
- Sparsentan; Sparsentan; Sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-08-12
- Completion
- 2027-04-12
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFocal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis +1 moreInterventionSparsentan; Sparsentan; SparsentanPhasePhase 2Registry statusRecruitingA Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
NCT04663204 · start 2020-12-10
Registered record
- Registry ID
- NCT04663204
- Conditions
- Immunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis; Autoimmune Diseases; Immune System Diseases
- Interventions
- Sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2020-12-10
- Completion
- 2027-12-31
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis +2 moreInterventionSparsentanPhasePhase 2Registry statusRecruitingStudy to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
NCT05562362 · start 2020-06-18
Registered record
- Registry ID
- NCT05562362
- Conditions
- Healthy Subjects
- Interventions
- RE-021, sparsentan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2020-06-18
- Completion
- 2020-11-12
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionRE-021, sparsentanPhasePhase 1Registry statusCompletedA Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850 · start 2018-12-11
Registered record
- Registry ID
- NCT03762850
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- sparsentan; irbesartan; Dapagliflozin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2018-12-11
- Completion
- 2026-07
- Enrolment
- 406
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmunoglobulin A NephropathyInterventionsparsentan; irbesartan; DapagliflozinPhasePhase 3Registry statusActive not recruitingStudy of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT03493685 · start 2018-04-17
Registered record
- Registry ID
- NCT03493685
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- sparsentan; Irbesartan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-04-17
- Completion
- 2026-03-19
- Enrolment
- 371
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFocal Segmental GlomerulosclerosisInterventionsparsentan; IrbesartanPhasePhase 3Registry statusCompletedRandomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
NCT01613118 · start 2014-03
Registered record
- Registry ID
- NCT01613118
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- RE-021 (Sparsentan); Irbesartan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-03
- Completion
- 2024-03-25
- Enrolment
- 109
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFocal Segmental GlomerulosclerosisInterventionRE-021 (Sparsentan); IrbesartanPhasePhase 2Registry statusCompleted